Alnylam Pharmace. sell Biotechhunter
Start price
03.09.20
/
50%
€105.70
Target price
04.09.20
-
Performance (%)
-1.80%
End price
04.09.20
€103.80
Summary
This prediction ended on 04.09.20 with a price of €103.80. With a performance of -1.80%, the SELL prediction by Biotechhunter was trending in the right direction. Biotechhunter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | 11.008% | 11.008% | 19.967% | 39.932% |
| iShares Core DAX® | 1,07 % | -0,52 % | 9,66 % | 59,63 % |
| iShares Nasdaq 100 | -0,49 % | -4,06 % | -0,13 % | 84,64 % |
| iShares Nikkei 225® | -2,03 % | 6,91 % | 26,86 % | 64,58 % |
| iShares S&P 500 | -0,10 % | -2,37 % | 0,51 % | 58,34 % |
Comments by Biotechhunter for this prediction
In the thread Alnylam Pharmace. diskutieren
Sell Alnylam Pharmace.